tirzepatide eu approval Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors say Tirzepatide: First Approval | Drugs

Novo Nordisk received FDA approval for its semaglutide-based GLP-1 products, Ozempic for diabetes and Wegovy for weight loss, in December 2017 and June 2021, respectively

Because compounded GLP-1 medications vary in quality and safety, medical oversight is essential for effective and responsible treatment

Weight loss is more than just looking better

Myth: I cant donate because there will be medication in my blood that will go to the recipient. Fact: Most medications, including GLP-1s, are present in such small amounts in a unit of blood that they do not affect the recipient

Demographic Trends Demographic trends generally drive market growth, particularly due to the rising prevalence of obesity among adults and adolescents

Urinary Tract Infections (UTIs) : The presence of excess glucose in the urine can also promote bacterial growth, leading to UTIs